Atreca Inc. (BCEL)
NASDAQ: BCEL
· Real-Time Price · USD
0.09
-0.00 (-1.32%)
At close: Jun 14, 2024, 7:28 PM
-1.32% (1D)
| Bid | n/a |
| Market Cap | 3.57M |
| Revenue (ttm) | 263K |
| Net Income (ttm) | -95.08M |
| EPS (ttm) | -2.5 |
| PE Ratio (ttm) | -0.036 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 122,115 |
| Avg. Volume (20D) | 267,000 |
| Open | 0.09 |
| Previous Close | 0.09 |
| Day's Range | 0.09 - 0.09 |
| 52-Week Range | 0.05 - 1.20 |
| Beta | 1.03 |
About BCEL
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, ...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 20, 2019
Employees 90
Stock Exchange NASDAQ
Ticker Symbol BCEL
Website https://www.atreca.com